Tenaya Therapeutics (TNYA) Competitors $0.61 0.00 (-0.29%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$0.61 0.00 (0.00%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. CMPX, TECX, SLDB, HUMA, RZLT, ARCT, PRTA, CYRX, AQST, and SNDLShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), Humacyte (HUMA), Rezolute (RZLT), Arcturus Therapeutics (ARCT), Prothena (PRTA), CryoPort (CYRX), Aquestive Therapeutics (AQST), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Compass Therapeutics Tectonic Therapeutic Solid Biosciences Humacyte Rezolute Arcturus Therapeutics Prothena CryoPort Aquestive Therapeutics SNDL Tenaya Therapeutics (NASDAQ:TNYA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has more risk & volatility, TNYA or CMPX? Tenaya Therapeutics has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Does the media refer more to TNYA or CMPX? In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 3 articles in the media. Compass Therapeutics' average media sentiment score of 0.65 beat Tenaya Therapeutics' score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TNYA or CMPX? 90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is TNYA or CMPX more profitable? Compass Therapeutics' return on equity of -42.47% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -92.20% -74.53% Compass Therapeutics N/A -42.47%-38.31% Do analysts prefer TNYA or CMPX? Tenaya Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 922.91%. Compass Therapeutics has a consensus target price of $12.67, suggesting a potential upside of 356.46%. Given Tenaya Therapeutics' higher probable upside, equities analysts plainly believe Tenaya Therapeutics is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has better earnings & valuation, TNYA or CMPX? Compass Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$111.13M-$1.16-0.53Compass Therapeutics$850K451.45-$49.38M-$0.41-6.77 SummaryCompass Therapeutics beats Tenaya Therapeutics on 9 of the 14 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.39M$2.89B$5.49B$9.01BDividend YieldN/A2.43%5.38%4.09%P/E Ratio-0.5321.5627.4220.26Price / SalesN/A245.52407.97121.21Price / CashN/A41.9536.6357.47Price / Book0.577.518.085.67Net Income-$111.13M-$55.05M$3.16B$248.47M7 Day Performance0.23%4.59%2.81%3.29%1 Month Performance16.01%4.86%3.68%5.19%1 Year Performance-79.00%5.82%35.29%21.35% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.1086 of 5 stars$0.61-0.3%$6.25+922.9%-79.0%$99.39MN/A-0.53110News CoverageCMPXCompass Therapeutics3.2404 of 5 stars$2.55+6.0%$13.13+415.7%+238.4%$352.06M$850K-6.2120Analyst UpgradeTECXTectonic Therapeutic3.6262 of 5 stars$18.81-5.0%$82.33+337.6%+38.6%$349.89MN/A-2.56120SLDBSolid Biosciences3.4398 of 5 stars$4.52-5.7%$14.90+230.0%-16.6%$349.18M$8.09M-1.51100Gap UpHUMAHumacyte2.3808 of 5 stars$2.21-4.5%$11.71+430.8%-60.1%$343.59M$1.57M-3.21150RZLTRezolute3.0399 of 5 stars$4.03-2.1%$11.83+194.0%+14.5%$342.50MN/A-3.4840ARCTArcturus Therapeutics3.7888 of 5 stars$12.49+1.6%$53.50+328.3%-37.8%$335.88M$152.31M-4.90180Analyst ForecastPRTAProthena2.8111 of 5 stars$6.08+6.3%$31.50+418.2%-67.8%$328.58M$135.16M-2.93130High Trading VolumeCYRXCryoPort2.143 of 5 stars$6.57+3.1%$11.00+67.5%+22.0%$328.07M$228.38M-2.801,186AQSTAquestive Therapeutics1.613 of 5 stars$3.30+1.4%$10.14+207.8%+54.4%$325.60M$57.56M-5.56160News CoverageSNDLSNDL3.3383 of 5 stars$1.24-1.2%$3.63+193.5%-34.9%$324.53M$671.81M-4.262,516News CoveragePositive News Related Companies and Tools Related Companies Compass Therapeutics Competitors Tectonic Therapeutic Competitors Solid Biosciences Competitors Humacyte Competitors Rezolute Competitors Arcturus Therapeutics Competitors Prothena Competitors CryoPort Competitors Aquestive Therapeutics Competitors SNDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
